Personalized Cancer Vaccine for Multiple Myeloma
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does not allow treatment with corticosteroids (except for low doses) or prior chemotherapy for smoldering multiple myeloma. Bisphosphonates are allowed.
What data supports the effectiveness of the treatment Vaccine Therapy for Multiple Myeloma?
Research shows that cancer vaccines, including those using dendritic cells (special immune cells), can trigger strong immune responses against multiple myeloma, potentially leading to long-term disease control. Additionally, combining vaccines with other treatments like lenalidomide has shown promise in maintaining remission in patients.12345
Is the personalized cancer vaccine for multiple myeloma safe for humans?
Research on cancer vaccines for multiple myeloma, including those using dendritic cells and other immune strategies, is ongoing. While specific safety data for personalized cancer vaccines is limited, studies have explored similar vaccine approaches in multiple myeloma, suggesting they are generally safe, but more research is needed to confirm this.12467
How is the personalized cancer vaccine treatment for multiple myeloma different from other treatments?
The personalized cancer vaccine for multiple myeloma is unique because it aims to generate a specific immune response against the cancer by using the patient's own immune cells, potentially leading to long-term immunity and fewer side effects compared to traditional chemotherapy. This approach involves using dendritic cells, which are powerful immune cells, to present myeloma-specific antigens and stimulate a targeted attack on the cancer cells.12358
What is the purpose of this trial?
This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.
Research Team
Krina Patel
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for adults with smoldering multiple myeloma at intermediate or high risk of progression. Participants must have certain levels of plasma cells, kidney function, and blood counts, and be able to consent. Excluded are those with active myeloma, prior SMM treatment, other cancers, infections like TB or hepatitis B/C, pregnant women, and people with HIV.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive personalized vaccine subcutaneously on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Treatment repeats every 28 days for up to 6 cycles.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Vaccine Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor